Do you want to read an article? Please log in or register.
Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study
Eur Respir J.
Nolan CM, Maddocks M, Maher TM, Banya W, Patel S, Barker RE, Jones SE, George PM, Cullinan P, Man WD
doi: 10.1183/13993003.
RECOMMENDED
Pulmonary Fibrosis
Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA, IPF-PRO™ Registry investigators.
doi: 10.1016/j.chest.2019.12.041.
Pulmonary Fibrosis
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
Lancet Respir Med.
Johannson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; Erice ILD Working Group
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Dirksen CD, Kimman ML, Wijsenbeek MS
doi: 10.1186/s12931-020-01458-1.
Pulmonary Fibrosis
Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study
Lancet Respir Med.
Herazo-Maya JD, Sun J, Molyneaux PL, Li Q, Villalba JA, Tzouvelekis A, Lynn H, Juan-Guardela BM, Risquez C, Osorio JC, Yan X, Michel G, Aurelien N, Lindell KO, Klesen MJ, Moffatt MF, Cookson WO, Zhang Y, Garcia JGN, Noth I, Prasse A, Bar-Joseph Z, Gibson KF, Zhao H, Herzog EL, Rosas IO, Maher TM, Kaminski N
doi: 10.1016/
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry
Eur Respir J.
Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, Klotsche J, Andreas S, Claussen M, Grohé C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Bahmer T, Oqueka T, Frankenberger M, Kreuter M
doi: 10.1183/13993003.02279-2019.
RECOMMENDED
Pulmonary Fibrosis
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
N Engl J Med.
Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators
doi: 10.1056/NEJMoa1811737.
RECOMMENDED
Pulmonary Fibrosis
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir Rev.
Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE
doi: 10.1183/16000617.0158-2019.
RECOMMENDED
Pulmonary Fibrosis
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, Flaherty KR, Kim HJ
doi: 10.1186/s12931-020-1315-4.